Acute Myeloid Leukemia Clinical Trial

RTX-240 Monotherapy and in Combination With Pembrolizumab

Summary

Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML) (Phase 1 only).

View Full Description

Full Description

This is a Phase 1/2, open label, multicenter, multidose, first-in-human (FIH) dose escalation and expansion study to determine the safety and tolerability, recommended phase 2 dose and optimal dosing interval, pharmacology, and antitumor activity of RTX-240 in adult patients with relapsed/refractory (R/R) or locally advanced solid tumors (Phase 1/2) or R/R acute myeloid leukemia (Phase 1 only), and RTX-240 in combination with pembrolizumab in adult patients with R/R or locally advanced solid tumors (Phase 1 only). RTX-240 is a cellular therapy that co-expresses 4-1BBL and IL-15TP, a fusion of IL-15 and IL-15 receptor alpha, with the goal of stimulating the innate and adaptive immune systems for the treatment of cancer. The study includes a monotherapy dose escalation phase (Phase 1) followed by an expansion phase (Phase 2) in specified tumor types.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Signed written informed consent obtained prior to study procedures
Patients ≥18 years with an ECOG 0 or 1 (Parts 1, 2 and 4) or 0-2 (Part 3).
Relapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no standard therapy exists (Parts 1, 2 and 4), or for which the patient is ineligible or has declined standard therapy or R/R, cytologically confirmed AML (Part 3).
Disease must be measurable per Response Evaluation Criteria
The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment.

Adequate Organ Function and Blood Cell Counts (Parts 1, 2, and 4) as defined by the protocol:

GFR ≥ 50 mL/min/1.73,
AST and ALT ≤ 3 × the ULN and total bilirubin ≤ 1.5 × ULN, in the absence of cancer within the liver
Or AST and ALT ≤ 5 × ULN and total bilirubin ≤ 3 × ULN, in the setting of primary or metastatic liver tumors.
ANC ≥ 1 × 10^3/μL without myeloid growth factor support for at least one week prior to enrollment
Platelet count ≥ 75 × 10^3/μL
Hemoglobin should be ≥ 9 g/dL without red blood cell transfusion for at least one week
Patients must have LVEF ≥ 45%
Patients enrolling into Part 2 of the study must be diagnosed with NSCLC, RCC, or anal cancers
Patients enrolling into Part 4 must be diagnosed with NSCLC or RCC
Patients enrolling into either Part 2 or 4 must have 2 or fewer prior treatment regimens. If patient received a prior PD-1/PD-L1-containing regimen, a prior response is required.

Exclusion Criteria:

Primary central nervous system (CNS) malignancy or CNS involvement, unless asymptomatic, previously treated, and stable without steroids (Parts 1, 2 and 4) or known CNS leukemia (Part 3).
Known hypersensitivity to any component of study treatment or excipients.
Positive antibody screen using institution's standard type and screen test.
Clinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
Clinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic anemia
Class III or IV cardiomyopathy per the New York Heart Association criteria
Leukemic blast count ≥ 25 x 10^3/µL (Part 3)
Concomitant conditions requiring active immunosuppression
History of clinically significant Grade 3 or higher immune related Adverse Event (irAE)
Prior malignancy within the past 3 years, with protocol specified exceptions
History of severe hypersensitivity to a PD-1/PD-L1 blocking Ab unless previously rechallenged successfully (Part 4)
Current noninfectious pneumonitis or a history of radiation pneumonitis or pneumonitis that required steroids, or Grade 2 or greater immune related pneumonitis, hepatitis, hypophysitis, or other endocrinopathy (Part 4)

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

166

Study ID:

NCT04372706

Recruitment Status:

Active, not recruiting

Sponsor:

Rubius Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

University of California San Diego
La Jolla California, 92093, United States
The Angeles Clinic & Research Institute
Los Angeles California, 90025, United States
Sarah Cannon Research Institute/ Colorado Blood Cancer Institute
Denver Colorado, 80218, United States
Sylvester Comprehensive Cancer Center/UMHC
Miami Florida, 33136, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Columbia University Medical Center
New York New York, 10032, United States
Oregon Health & Sciences University - Knight Cancer Institute
Portland Oregon, 97239, United States
Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States
UPMC Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
Virginia Cancer Specialists
Fairfax Virginia, 22031, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

166

Study ID:

NCT04372706

Recruitment Status:

Active, not recruiting

Sponsor:


Rubius Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.